Autoimmune hepatitis
ORPHA:2137DiseaseNot applicableAdolescent, Adult, Childhood, Elderly
Фенотипы (HPO)34
Облигатный (100%)2
HP:0003237Increased circulating IgG level
HP:0010702Increased circulating antibody level
Очень частый (80–99%)7
HP:0002910Elevated circulating hepatic transaminase concentration
HP:0003262Smooth muscle antibody positivity
HP:0003453Antineutrophil antibody positivity
HP:0003493Antinuclear antibody positivity
HP:0030908Liver kidney microsome type 1 antibody positivity
HP:0030909Anti-liver cytosolic antigen type 1 antibody positivity
HP:0031925Rosette
Частый (30–79%)6
HP:0000716Depression
HP:0002027Abdominal pain
HP:0002829Arthralgia
HP:0012432Chronic fatigue
HP:0012522Spider hemangioma
HP:0032469Anti-asialoglycoprotein receptor antibody positivity
Периодический (5–29%)16
HP:0000099Glomerulonephritis
HP:0000739Anxiety
HP:0000952Jaundice
HP:0001045Vitiligo
HP:0001369Arthritis
HP:0001394Cirrhosis
HP:0001541Ascites
HP:0001744Splenomegaly
HP:0002037Inflammation of the large intestine
HP:0002239Gastrointestinal hemorrhage
HP:0003573Increased total bilirubin
HP:0006555Diffuse hepatic steatosis
HP:0030991Sclerosing cholangitis
HP:0100279Ulcerative colitis
HP:0100646Thyroiditis
HP:0200119Acute hepatitis
Очень редкий (1–4%)3
HP:0001402Hepatocellular carcinoma
HP:0004787Fulminant hepatitis
HP:0006562Viral hepatitis
Эпидемиология17
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | — | Europe | Class only |
| Annual incidence | 1-9 / 100 000 | 1.2 | Worldwide | Value and class |
| Point prevalence | 1-5 / 10 000 | 23.5 | Worldwide | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.75 | Europe | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.9 | Norway | Value and class |
| Point prevalence | 1-5 / 10 000 | 16.9 | Norway | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.85 | Sweden | Value and class |
| Point prevalence | 1-5 / 10 000 | 24.5 | New Zealand | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.95 | Spain | Value and class |
| Point prevalence | 1-5 / 10 000 | 11.6 | Spain | Value and class |
| Point prevalence | 1-5 / 10 000 | 10.7 | Sweden | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.67 | Israel | Value and class |
| Point prevalence | 1-5 / 10 000 | 11 | Israel | Value and class |
| Annual incidence | 1-9 / 100 000 | 1.68 | Denmark | Value and class |
| Point prevalence | 1-5 / 10 000 | 23.9 | Denmark | Value and class |
| Point prevalence | 1-9 / 100 000 | 4 | Singapore | Value and class |
| Point prevalence | 1-5 / 10 000 | 42.9 | Specific population | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)